| Radmehr Torabi, MD | |
|
593 Eddy St, Providence, RI 02903-4923 | |
| (401) 455-1749 | |
| (401) 455-1292 |
| Full Name | Radmehr Torabi |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 15 Years |
| Location | 593 Eddy St, Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730472820 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | LP02235 (Rhode Island) | Secondary |
| 207T00000X | Neurological Surgery | MD17291 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Rhode Island Hospital | Providence, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lifespan Physician Group Inc | 2567455082 | 631 |
| Rhode Island Hospital | 8921900044 | 303 |
News Archive
Janssen announced today that the U.S. Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication ZYTIGA (abiraterone acetate).
Researchers have identified a protein in the brain that halts the progression of Alzheimer's disease in human brain tissue. The protein, known as "transthyretin," protects brain cells from gradual deterioration by blocking another toxic protein that contributes to the disease process.
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced that its Investigational New Drug Application (IND) for its Multimeric-001 vaccine (M-001), has been accepted by the US Food and Drug Administration, and the Company was notified by its regulatory advisors that the 'study may proceed'.
The Contra Costa Times: "Six months after passage of the federal health reform law, major provisions will kick in that supporters say will make it easier for Americans to get and keep health insurance. … Among the major changes: Insurance companies will no longer be able to cancel policies because someone becomes sick, set lifetime caps on coverage or deny insurance to children with pre-existing conditions. … In addition to enabling young people to remain on their parents' policies up to age 26, several other major provisions kick in on Thursday.
Researchers at the Hebrew University of Jerusalem have discovered a group of substances in the body that play a key role in controlling bone density, and on this basis they have begun development of a drug for prevention and treatment of osteoporosis and other bone disorders.
› Verified 4 days ago
| Entity Name | Lifespan Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407116643 PECOS PAC ID: 2567455082 Enrollment ID: O20121029000368 |
News Archive
Janssen announced today that the U.S. Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication ZYTIGA (abiraterone acetate).
Researchers have identified a protein in the brain that halts the progression of Alzheimer's disease in human brain tissue. The protein, known as "transthyretin," protects brain cells from gradual deterioration by blocking another toxic protein that contributes to the disease process.
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced that its Investigational New Drug Application (IND) for its Multimeric-001 vaccine (M-001), has been accepted by the US Food and Drug Administration, and the Company was notified by its regulatory advisors that the 'study may proceed'.
The Contra Costa Times: "Six months after passage of the federal health reform law, major provisions will kick in that supporters say will make it easier for Americans to get and keep health insurance. … Among the major changes: Insurance companies will no longer be able to cancel policies because someone becomes sick, set lifetime caps on coverage or deny insurance to children with pre-existing conditions. … In addition to enabling young people to remain on their parents' policies up to age 26, several other major provisions kick in on Thursday.
Researchers at the Hebrew University of Jerusalem have discovered a group of substances in the body that play a key role in controlling bone density, and on this basis they have begun development of a drug for prevention and treatment of osteoporosis and other bone disorders.
› Verified 4 days ago
| Entity Name | Rhode Island Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154537520 PECOS PAC ID: 8921900044 Enrollment ID: O20141017000105 |
News Archive
Janssen announced today that the U.S. Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication ZYTIGA (abiraterone acetate).
Researchers have identified a protein in the brain that halts the progression of Alzheimer's disease in human brain tissue. The protein, known as "transthyretin," protects brain cells from gradual deterioration by blocking another toxic protein that contributes to the disease process.
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced that its Investigational New Drug Application (IND) for its Multimeric-001 vaccine (M-001), has been accepted by the US Food and Drug Administration, and the Company was notified by its regulatory advisors that the 'study may proceed'.
The Contra Costa Times: "Six months after passage of the federal health reform law, major provisions will kick in that supporters say will make it easier for Americans to get and keep health insurance. … Among the major changes: Insurance companies will no longer be able to cancel policies because someone becomes sick, set lifetime caps on coverage or deny insurance to children with pre-existing conditions. … In addition to enabling young people to remain on their parents' policies up to age 26, several other major provisions kick in on Thursday.
Researchers at the Hebrew University of Jerusalem have discovered a group of substances in the body that play a key role in controlling bone density, and on this basis they have begun development of a drug for prevention and treatment of osteoporosis and other bone disorders.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Radmehr Torabi, MD 593 Eddy St, Providence, RI 02903-4923 Ph: (401) 455-1749 | Radmehr Torabi, MD 593 Eddy St, Providence, RI 02903-4923 Ph: (401) 455-1749 |
News Archive
Janssen announced today that the U.S. Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication ZYTIGA (abiraterone acetate).
Researchers have identified a protein in the brain that halts the progression of Alzheimer's disease in human brain tissue. The protein, known as "transthyretin," protects brain cells from gradual deterioration by blocking another toxic protein that contributes to the disease process.
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced that its Investigational New Drug Application (IND) for its Multimeric-001 vaccine (M-001), has been accepted by the US Food and Drug Administration, and the Company was notified by its regulatory advisors that the 'study may proceed'.
The Contra Costa Times: "Six months after passage of the federal health reform law, major provisions will kick in that supporters say will make it easier for Americans to get and keep health insurance. … Among the major changes: Insurance companies will no longer be able to cancel policies because someone becomes sick, set lifetime caps on coverage or deny insurance to children with pre-existing conditions. … In addition to enabling young people to remain on their parents' policies up to age 26, several other major provisions kick in on Thursday.
Researchers at the Hebrew University of Jerusalem have discovered a group of substances in the body that play a key role in controlling bone density, and on this basis they have begun development of a drug for prevention and treatment of osteoporosis and other bone disorders.
› Verified 4 days ago
Dr. Elias Shaaya, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-793-9135 | |
Dr. Ki-eun Chang, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy Street Apc 6, Providence, RI 02903 Phone: 401-793-9166 Fax: 401-444-2788 | |
Dr. Belinda Shao, MD, MPH Neurological Surgery Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-793-9135 Fax: 401-444-2788 | |
Dr. Petra Margarete Klinge, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 55 Claverick Street, Providence, RI 02903 Phone: 401-455-1749 Fax: 401-455-1292 | |
Sohail Syed, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Apc 6, Providence, RI 02903 Phone: 401-444-4146 Fax: 401-444-2781 | |
Albert Edward Telfeian, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Apc 6, Providence, RI 02903 Phone: 401-793-9153 Fax: 401-444-2024 | |
Dr. Beverly Claire Walters, M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 128 N Main St, Providence, RI 02903 Phone: 401-351-1369 Fax: 401-251-0079 |